A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 447-457

  Perez Marrero, Ramon ^a   Tyler, Robert C ^b  

^a Urology Health Center   (United States)

^b QLT Inc   (United States)

Author keywords

Leuprolide acetate; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; ANTIANDROGEN; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; POLYGLACTIN; POLYMER; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ABSCESS; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DESENSITIZATION; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; GYNECOMASTIA; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS; LUTEINIZING HORMONE RELEASE; MALAISE; MALE; MORTALITY; MYOFIBROSIS; NERVE INJURY; ORCHIECTOMY; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; PRURITUS; SKIN DISCOLORATION; SKIN IRRITATION; STRUCTURE ANALYSIS; SUSTAINED RELEASE FORMULATION; SUSTAINED RELEASE PREPARATION; TESTIS ATROPHY; THROMBOSIS; TREATMENT INDICATION;

CLINICAL TRIALS, PHASE I; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; MALE; MULTICENTER STUDIES; PROSTATIC NEOPLASMS;

EID: 1242296770     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.447     Document Type: Article

References (47)

1. GROSSFELD GD, CARROLL PR: Natural History. In: Prostate Cancer. Grossfeld GD, Carroll PR (Eds), BC Decker, London, UK (2002):149-163.
2. KATTAN MW, FEARN PA, LEIBEL S, POTTERS L: The definition of biochemical failure in patients treated with definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2000) 48:1469-1474.
3. GRETZER MB, TROCK BJ, HAN M, WALSH PC: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J. Urol. (2002) 168:1419-1422.
4. GLEAVE ME, LA BIANCA SE, GOLDENBERG SL, JONES EC, BRUCHOVSKY N, SULLIVAN LD: Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology (2000) 56:289-294.
5. MEYER F, BAIRATI I, BEDARD C, LACOMBE L, TETU B, FRADET Y: Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology (2001) 58:71-77.
6. STONE NN, STOCK RG: Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer. Mol. Urol. (1999) 3:239-244.
7. HUGGINS C, HODGES CV: Studies on prostate cancer; effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. (1941) 1:293-297.
8. ARIMURA A, SCHALLY AV: Physiological and clinical studies with natural and synthetic luteinizing hormone-releasing hormone (LH-RH). Med. J. Osaka. Univ. (1972) 23:77-100.
9. TOLIS G, ACKMAN D, STELLOS A et al.: Tumour growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA (1982) 79:1658-1662.
10. PEELING WB: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology (1989) 33:45-52.
11. SHARIFI R, LEE M, OJEDA L, RAY P, STOBNICKI M, GUINAN P: Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology (1985) 26:117-124.
12. BOUCHOT O, SORET JY, JACQMIN D, LAHLOU N, ROGER M, BLUMBERG J: Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and harmacokinetic multicenter study. Horm. Res. (1998) 50:89-93.
13. CHU FM, JAYSON M, DINEEN MK, PEREZ R, HARKAWAY R, TYLER RC: A clinical study of 22.5 mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J. Urol. (2002) 168:1199-1203.
14. FERNANDEZ DM, DIJKMAN GA, DEBRUYNE FM, WITJES WP, KOLVENBAG GJ: Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology (1996) 48:894-900.
15. SARTOR AO, DINEEN MK, PEREZ-MARRENO R, CHU F, CARRON G, TYLER RC: an eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology (2003) 62:319-323.
16. SHARIFI R, BRUSKEWITZ RC, GITTLEMAN MC, GRAHAM SD Jr, HUDSON PB, STEIN B: Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin. Ther. (1996) 18:647-657.
17. SHARIFI R, KNOLL LD, SMITH J, KRAMOLOWSKY E: Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology (1998) 51:271-276.
18. VOGELZANG NJ, CHODAK GW, SOLOWAY MS et al.: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 46:220-226.
19. KAWAKAMI J, MORALES A: A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J. Urol. (2002) 167:288.
20. OEFELEIN MG, CORNUM R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J. Urol. (2000) 164:726-729.
21. PEREZ-MARRENO R, CHU FM, GLEASON D, LOIZIDES E, WACHS B, TYLER RC: A six-month, open-label study assessing a new formulation of 7.5 mg leuprolide for suppression of testosterone in patients with prostate cancer. Clin. Ther. (2002) 24:1902-1914.
22. BAHNSON RR, HANKS GE, HUBEN RP et al.: NCCN Practice Guidelines for Prostate Cancer. Oncology (Huntingt) (2000) 14:111-119.
23. OEFELEIN MG, RESNICK MI: Effective testosterone suppression for patients with prostate cancer: is ther a best castration? Urology (2003) 62:207-213.
24. SHARIFI R, SOLOWAY M: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J. Urol. (1990) 143:68-71.
25. BUBLEY GJ: Is the flare phenomenon clinically significant? Urology (2001) 58:5-9.
26. SCALETSCKY R, SMITH JA: Disease flare with gonadotropin-releasing hormone (GnRH) analogues. How serious is it? Drug Saf. (1993) 8:265-270.
27. EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. (1998) 339:1036-1042.
28. CRAWFORD ED, EISENBERGER MA, MCLEOD DG et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. (1989) 321:419-424.
29. CAUBET JF, TOSTESON TD, DONG EW et al.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology (1997) 49:71-78.
30. LEIBOWITZ RL, TUCKER SJ: Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist (2001) 6:177-182.
31. BYAR DP: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer (1973) 32:1126-1130.
32. BYAR DP, CORLE DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. (1988) 7:165-170.
33. CRAWFORD ED: Early versus late hormonal therapy: debating the issues. Urology (2003) 61:8-13.
34. SOLOWAY MS, SHARIFI R, WAJSMAN Z, MCLEOD D, WOOD DP Jr, PURAS-BAEZ A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. (1995) 154:424-428.
35. FAIR WR, RABBANI F, A BASTAR, BETANCOURT J: Neoadjuvant Hormone Therapy Before Radical Prostatectomy: update on the Memorial Sloan-Kettering Cancer Center Trials. Mol. Urol. (1999) 3:253-260.
36. MESSING EM, MANOLA J, SAROSDY M, WILDING G, CRAWFORD ED, TRUMP D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. (1999) 341:1781-1788.
37. D'AMICO AV, SCHULTZ D, LOFFREDO M et al.: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA (2000) 294:1280-1283.
38. BOLLA M, COLLETTE L, BLANK L et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet (2002) 360:103-106.
39. KUCWAY R, VICINI F, HUANG R, STROMBERG J, GONZALEZ J, MARTINEZ A: Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J. Urol. (2002) 167:2443-2447.
40. LEE LN, STOCK RG, STONE NN: Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int. J. Radiat. Oncol. Biol. Phys. (2002) 52:444-452.
41. NICOLL LH, HESBY A: Intramuscular injection: an integrative research review and guideline for evidence-based practice. Appl. Nurs. Res. (2002) 15:149-162.
42. CURRY EA 3rd, SWEENEY CJ: Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. J. Urol. (2002) 168:193.
43. TUNN UW, BARGELLONI U, COSCIANI S, FIACCAVENTO G, GUAZZIERI S, PAGANO F: Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and harmacokinetic profile in patients with advanced prostate cancer. Urol. Int. (1998) 60(Suppl. 1):9-16.
44. SEELY JH: Phase III studies in prostatic cancer with leuprolide acetate. J. Androl. (1987) 8:S23-S26.
45. WOJCIECHOWSKI NJ, CARTER CA, SKOUTAKIS VA, BESS DT, FALBE WJ, MICKLE TR: Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell. Clin. Pharm. (1986) 20:746-751.
46. MILLIKAN R, LOGOTHETIS C: Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Huntingt) (1997) 11:180-193.
47. BRUCHOVSKY N, KLOTZ LH, SADAR M et al.: Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol. Urol. (2000) 4:191-199.